DK1253935T3 - Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde - Google Patents

Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde

Info

Publication number
DK1253935T3
DK1253935T3 DK01902406T DK01902406T DK1253935T3 DK 1253935 T3 DK1253935 T3 DK 1253935T3 DK 01902406 T DK01902406 T DK 01902406T DK 01902406 T DK01902406 T DK 01902406T DK 1253935 T3 DK1253935 T3 DK 1253935T3
Authority
DK
Denmark
Prior art keywords
growth factor
stroke
prevent
ischemic disease
placental growth
Prior art date
Application number
DK01902406T
Other languages
English (en)
Inventor
Desire Collen
Peter Carmeliet
Original Assignee
D Collen Res Foundation Vzw
Flanders Interuniversity Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by D Collen Res Foundation Vzw, Flanders Interuniversity Inst filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of DK1253935T3 publication Critical patent/DK1253935T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
  • Clamps And Clips (AREA)
DK01902406T 2000-02-04 2001-02-05 Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde DK1253935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
US23659400P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
DK1253935T3 true DK1253935T3 (da) 2006-09-04

Family

ID=26243563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902406T DK1253935T3 (da) 2000-02-04 2001-02-05 Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde

Country Status (9)

Country Link
EP (1) EP1253935B1 (da)
JP (1) JP4969753B2 (da)
AT (1) ATE324905T1 (da)
AU (2) AU4643501A (da)
DE (1) DE60119285T2 (da)
DK (1) DK1253935T3 (da)
ES (1) ES2263582T3 (da)
PT (1) PT1253935E (da)
WO (2) WO2001057181A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604024A4 (en) * 2000-04-06 2008-04-23 Wayne P Franco METHODS OF USING GROWTH FACTORS FOR TREATING CARDIOPATHY
JP2005526482A (ja) * 2001-08-10 2005-09-08 イムクローン システムズ インコーポレイティド Ｖｅｇｆｒ−１を発現する幹細胞の単離および動員
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
ATE394679T1 (de) 2002-11-16 2008-05-15 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
EP2295449A1 (en) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimeric form
EP3586867A3 (en) * 2013-01-28 2020-04-08 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
ES2251740T3 (es) * 1996-08-23 2006-05-01 Ludwig Institute For Cancer Research Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
CN1260835A (zh) * 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
WO1999040197A2 (en) * 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: vegf

Also Published As

Publication number Publication date
AU4643501A (en) 2001-08-14
WO2001056593A2 (en) 2001-08-09
EP1253935A2 (en) 2002-11-06
ES2263582T3 (es) 2006-12-16
ATE324905T1 (de) 2006-06-15
AU2001230243A1 (en) 2001-08-14
EP1253935B1 (en) 2006-05-03
WO2001057181A2 (en) 2001-08-09
DE60119285T2 (de) 2007-05-10
DE60119285D1 (de) 2006-06-08
PT1253935E (pt) 2006-08-31
JP4969753B2 (ja) 2012-07-04
JP2003521522A (ja) 2003-07-15
WO2001056593A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
BR0114390A (pt) éteres de 7-desmetilrapamicina
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE60206512D1 (de) Rapanycin29-enole
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
PT1187918E (pt) Antagonistas de tek
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
DK1334194T3 (da) Afbildning, diagnosticering og behandling af sygdom
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
AR028411A1 (es) Secuencias de nuclentidos relacionadas con el aumento o la disminucion del endice de ovulacion en mameferos
TR200200278T2 (tr) Kalsilitik bileşimler
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60003074D1 (de) Fusidinsäure-derivate
ECSP045161A (es) Piperidin-2,6-diona sustituida con heterociclo en la posición 3
DK1311486T3 (da) Anvendelser af thaliporphin eller dets derivater til behandling af hjertesygdomme og fremstilling af samme
ATE390144T1 (de) Behandlung von fibrosen